Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

We investigated the role of mesothelin (Msln) and thymocyte differentiation antigen 1 (Thy1) in the activation of fibroblasts across multiple organs and demonstrated that Msln(−/−) mice are protected from cholestatic fibrosis caused by Mdr2 (multidrug resistance gene 2) deficiency, bleomycin-induced...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Proc Natl Acad Sci U S A
Asıl Yazarlar: Nishio, Takahiro, Koyama, Yukinori, Liu, Xiao, Rosenthal, Sara B., Yamamoto, Gen, Fuji, Hiroaki, Baglieri, Jacopo, Li, Na, Brenner, Laura N., Iwaisako, Keiko, Taura, Kojiro, Hagood, James S., LaRusso, Nicholas F., Bera, Tapan K., Pastan, Ira, Brenner, David A., Kisseleva, Tatiana
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2021
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307749/
https://ncbi.nlm.nih.gov/pubmed/34253615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2101270118
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller